Researchmoz presents this most up-to-date research on"Ulcerative
Colitis Kappaproct and Remicade Forecast and Market Analysis to 2022".
The report focuses primarily on quantitative market metrics in order to
characterize the growth and evolution of the Remote Patient Monitoring
Market.
Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022 http://www.researchmoz.us/kappaproct-ulcerative-colitis-forecast-and-market-analysis-to-2022-report.html
InDeX Pharmaceuticals is a biopharmaceutical company that focuses on
the discovery and development of immunological treatments for diseases
with a high unmet need. The company is dedicated to developing
personalized treatments and diagnostic assays that will allow physicians
to predict which patient populations will respond to specific
biologics. InDeX developed Kappaproct with the goal of addressing a
significant unmet need in severe UC patients, which is the lack of an
effective treatment.During the forecast period from 2012-2022, the growth of the UC market
will be driven largely by the entry of Johnson & Johnsons (J&Js)
Simponi and Takedas Entyvio, which will lead to an increase in the
overall number of patients being treated with biologics in the US, 5EU,
Japan, and Canada. Another key event affecting the UC market is the
anticipated launch of biosimilars, given that the patent expiry of the
UC blockbusters, Remicade and Humira are set to expire in the US in 2018
and 2016, respectively.
Browse Research Reports On Healthcare @ http://www.researchmoz.us/healthcare-market-reports-56.html
Scope
Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Kappaproct including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Kappaproct for the top five countries from 2012 to 2022.
Sales information covered for France, Germany, Italy, Spain and the UK.
Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Kappaproct including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Kappaproct for the top five countries from 2012 to 2022.
Sales information covered for France, Germany, Italy, Spain and the UK.
Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022 http://www.researchmoz.us/remicade-ulcerative-colitis-forecast-and-market-analysis-to-2022-report.html
Remicade (infliximab) is a TNF-a inhibitor that was originally developed
by Centocor Ortho Biotech, which is now Janssen Biotech, a subsidiary
of J&J. Upon the onset of intestinal inflammation in IBD, a rather
aggravated immune response is initiated that is skewed towards a
specific T-cell phenotype. This T-cell group (Th1) is attracted to the
site of inflammation, where additional white blood cells are recruited.
Th1 cells produce large amounts of an inflammatory protein called INF-?,
which, in turn, induces the production of the pro-inflammatory cytokine
TNF-a in both local and recruited macrophages, as well as in the
intestinal epithelial cells.During the forecast period from 2012-2022, the growth of the UC market
will be driven largely by the entry of Johnson & Johnsons (J&Js)
Simponi and Takedas Entyvio, which will lead to an increase in the
overall number of patients being treated with biologics in the US, 5EU,
Japan, and Canada. Another key event affecting the UC market is the
anticipated launch of biosimilars, given that the patent expiry of the
UC blockbusters, Remicade and Humira are set to expire in the US in 2018
and 2016, respectively.
For More Details Contact At :
Web: http://www.researchmoz.us
Web: http://www.researchmoz.us
0 comments:
Post a Comment